title: Safety, tolerance, and pharmacokinetics of atevirdine mesylate (U-87201E) in asymptomatic human immunodeficiency virus-infected patients.
abstract: Atevirdine mesylate (U-87201E) is a new nonnucleoside (bisheteroarylpiperazine) inhibitor of human immunodeficiency virus type 1 reverse transcriptase. In a double-blind, escalating single-dose study the safety, tolerance, and pharmacokinetics of atevirdine mesylate were investigated in 24 asymptomatic human immunodeficiency virus-seropositive male patients. Each patient received one single oral dose of atevirdine mesylate and placebo separated by an interval of 1 to 3 weeks. For each dose level (400, 800, 1,200, and 1,600 mg) six patients received drug and placebo on separate occasions. Blood samples were collected before dosing and at intervals afterward for safety evaluation and estimation of atevirdine and metabolite levels. The concentrations of atevirdine and its principal metabolite (U-89255) in serum were determined by high-performance liquid chromatography. The results of the study showed that atevirdine mesylate is well tolerated at all dose levels. No clinically significant effects on vital signs, electrocardiograms, or laboratory tests were observed. Occasional headache and nausea were reported both in the drug group and in the placebo group. The times to peak values were relatively short (0.5 to 1.0 h), suggesting a rapid absorption. The maximum concentrations of drug in serum were 1.4 microM (400 mg), 4.2 microM (800 mg), 7.3 microM (1,200 mg), and 5.8 microM (1,600 mg). The values of the pharmacokinetic parameters for atevirdine were found to have relatively large intersubject variabilities, and consequently, the study had little power to detect dose-dependent changes in the values of the pharmacokinetic parameters. The oral clearance of atevirdine tended to increase by 90% as the atevirdine mesylate doses increased from 400 to 1,600 mg, but this change in oral clearance was not statistically significant. The values of the pharmacokinetic parameters determined in the study were similar to those found in a previous single-dose study in healthy volunteers.
authors.affiliation: Department of Internal Medicine, University Hospital Utrecht, The Netherlands.
authors.forename: A M
authors.initials: AM
authors.lastname: Been-Tiktak
authors.forename: H M
authors.initials: HM
authors.lastname: Vrehen
authors.forename: M M
authors.initials: MM
authors.lastname: Schneider
authors.forename: M
authors.initials: M
authors.lastname: van der Feltz
authors.forename: T
authors.initials: T
authors.lastname: Branger
authors.forename: P
authors.initials: P
authors.lastname: Ward
authors.forename: S R
authors.initials: SR
authors.lastname: Cox
authors.forename: J D
authors.initials: JD
authors.lastname: Harry
authors.forename: J C
authors.initials: JC
authors.lastname: Borleffs
mesh_terms: D000328:Adult; D000998:Antiviral Agents / Q000009:adverse effects* / Q000493:pharmacokinetics*; D004311:Double-Blind Method; D006679:HIV Seropositivity / Q000378:metabolism*; D015497:HIV-1; D006801:Humans; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000009:adverse effects* / Q000493:pharmacokinetics*
chemical_list: D000998:Antiviral Agents; D010879:Piperazines; C076632:atevirdine